Menu
GeneBe

HBE1

hemoglobin subunit epsilon 1, the group of Hemoglobin subunits

Basic information

Region (hg38): 11:5268344-5505652

Links

ENSG00000213931NCBI:3046OMIM:142100HGNC:4830Uniprot:P02100AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

No genCC data.

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the HBE1 gene.

  • Inborn genetic diseases (149 variants)
  • not provided (6 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the HBE1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
0
missense
6
clinvar
6
nonsense
0
start loss
0
frameshift
0
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
0
non coding
130
clinvar
16
clinvar
3
clinvar
149
Total 0 0 136 16 3

Variants in HBE1

This is a list of pathogenic ClinVar variants found in the HBE1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
11-5268499-G-A HBE1-related disorder Likely benign (Dec 26, 2019)3043301
11-5268510-C-G not specified Uncertain significance (Nov 08, 2022)3104401
11-5269543-T-C HBE1-related disorder Likely benign (May 17, 2022)3056068
11-5269561-T-A not specified Uncertain significance (Nov 17, 2022)2326883
11-5269592-G-A HBE1-related disorder Likely benign (May 02, 2019)3037396
11-5269629-C-A not specified Uncertain significance (Aug 02, 2021)2405147
11-5269817-C-G not specified Uncertain significance (Dec 06, 2022)2333867
11-5269858-G-A HBE1-related disorder Benign (Oct 28, 2019)3040733
11-5269863-C-T not specified Uncertain significance (May 16, 2023)2546793
11-5269884-G-A not specified Uncertain significance (Dec 13, 2022)2403576
11-5269887-C-G not specified Uncertain significance (Aug 02, 2021)2240284
11-5284246-AAGCTAAGCTTTCATTAAAAAAAGTCTAACCAGCTGCATTCGACTTTGACTGCAGCAGCTGGTTAGAAGGTTCTACTGGAGGAGGGTCCCAGCCCATTGCTAAATTAACATCAGGCTCTGAGACTGGCAGTATATCTCTAACAGTGGTTGATGCTATCTTCTGGAACTTGCCTGCTACATTGAGACCACTGACCCATACATAGGAAGCCCATAGCTCTGTCCTGAACTGTTAGGCCACTGGTCCAGAGAGTGTGCATCTCCTTTGATCCTCATAATAACCCTATGAGATAGACACAATTATTACTCTTACTTTATAGATGATGATCCTGAAAACATAGGAGTCAAGGCACTTGCCCCTAGCTGGGGGTATAGGGGAGCAGTCCCATGTAGTAGTAGAATGAAAAATGCTGCTATGCTGTGCCTCCCCCACCTTTCCCATGTCTGCCCTCTACTCATGGTCTATCTCTCCTGGCTCCTGGGAGTCATGGACTCCACCCAGCACCACCAACCTGACCTAACCACCTATCTGAGCCTGCCAGCCTATAACCCATCTGGGCCCTGATAGCTGGTGGCCAGCCCTGACCCCACCCCACCCTCCCTGGAACCTCTGATAGACACATCTGGCACACCAGCTCGCAAAGTCACCGTGAGGGTCTTGTGTTTGCTGAGTCAAAATTCCTTGAAATCCAAGTCCTTAGAGACTCCTGCTCCCAAATTTACAGTCATAGACTTCTTCATGGCTGTCTCCTTTATCCACAGAATGATTCCTTTGCTTCATTGCCCCATCCATCTGATCCTCCTCATCAGTGCAGCACAGGGCCCATGAGCAGTAGCTGCAGAGTCTCACATAGGTCTGGCACTGCCTCTGACATGTCCGACCTTAGGCAAATGCTTGACTCTTCTGAGCTCAGTCTTGTCATGGCAAAATAAAGATAATAATAGTGTTTTTTTATGGAGTTAGCGTGAGGATGGAAAACAATAGCAAAATTGATTAGACTATAAAAGGTCTCAACAAATAGTAGTAGATTTTATCGTCCATTAATCCTTCCCTCTCCTCTCTTACTCATCCCATCACGTATGCCTCTTAATTTTCCCTTACCTATAATAAGAGTTATTCCTCTTATTATATTCTTCTTATAGTGATTCTGGATATTAAAGTGGGAATGAGGGGCAGGCCACTAACGAAGAAGATGTTTCTCAAAGAAGCCATTCTCCCCACATAGATCATCTCAGCAGGGTTCAGGAAGATAAAGGAGGATCAAGGTCGAAGGTAGGAACTAAGGAAGAACACTGGGCAAGTGGATCCAGGTTGTCCAACGCTGAAAGTAGGAATCTAAGCACTAGTCTCTGGATGCTAGGAGGGCCTCTGCATGGGTAACTCTTTCAACTAGCCAGGGGCTGGACTGTGGAGAAACCATTTCCAGATAGAAGTGAGGAGATTCCAGCAGGAAACACTTAAGAGAGGATCCCTGGAAGTTCGGGGCAGGAGGCTCCCTGTCACATGAAGGAAACCTGCTCAGCGTAGGCTCTAGGTTCTTCCCTACTCTTATCCAATGGGGCTTCTGATTTTAAGCCAGTCTTCACAAAGCCCCAGATTTCTACATGCTGGAGCCCTGAATGGGCAGGAAGCATTGCGGTTTCCATTTCATTCAGAGCTCTTTCATACCCTGCTTCCCCATAGTTTGTCTCAACATTTCTGTTGATAATCTGATTCATGCAACCAAGAATTATGAGAGAGCCTTCAGTCATGCCTAGGCCTGCATTTATTGTTGTGCATATGATGGGGTAGCAGACAAGAAAACGTTAACAGCATAGACTTTCTCAGAGCTATATGAGTTTGGGAATTAATCAAGACCAGCCTTTTGCTCAGGGTAGAAATCCCCTATAGGGATTTATTCAATGATGGGTTAAAAGCTTTCTATATGGTGAGGAGCTCACAGATTTTCCAAGCCCTTGCTTTTGCTAGACAGCTTAATGTTTATGAAATTCTTACACACAGAAGAATCTTCTAATCCTGGGTTACATAATATAACTTGATTCCCTATTCCAGAAGATAATATTCCCATATTCTGAAGCATTCATGCATTTGTTAAATAATAGGCATAGTGACAAGTGCCAGAACTCTAACAGTCAACCAGAGAGCCACAGTTTTCAACTTCACAAAGTTAACCATCTAACTGAAGACAGCAGCAATCAAAACCACCACCCCTTCTCCACATGGTGTAGTCTTTCCTGATGTCAGGGATGTTAGGCTCAGGTTAGGAAAGTCAGACTATCATCCCAGAGCAGGACACAGACGAATAAAGTGTAATTTTTTAGTCACTTAGGAAAAACAGTGGAATGCAAAGAGTAAAAAATGCTTTCTGAATGGATAACTTGGCCTGGGAGGCCTTTGGAAGCAGAGACTGGAGCTTAAATTTAAACATCTTTGTATCCCCAGCATCCAGCATACAGACTGCCAAGAAGTACATGTCAATAAATATTTATTGGATAGTGAGCAAAGACATAATTAGGACCAAATCTCAATTCTACTATTTGCTAGTAGTTTATGTTTGTGTGTGTGAGAGTGTATGCTTGAGCAAGTTGAGAGGTAGTTTTTTTAACTGTAGTAAAATGGGGATAATAATAGTATCTACCTGAAAGAATCCAAGAGTATTAAATATGATTAATTATGCAAAGCACTAATTACAGTCTCTGATAGCCTTCAATAAATGTCAGTTATTTTTATTATTACAGTTAAAGATGAATGGGCATAAAGTACAGAACACTAGTTTTCACCTGCAGCAAGAATGATTGCAGTTAAACAAAAAATACTAGCAAACATTTCTAGAGTAGTTAGCATTTATAAGTCACTGCTTTAAACTCTTTGCATGTATTAACTCACTCGGGCTGCAGAACAATCTTATGAGCCTGTTAAAACTCCTGTAATCATGCTTATAATCCCAGCACTTTGGAAGGCTGAGGTGGGCAGATTGCTTGAGCTCCGGAGTCTGAGACCATCCTGTGTAACATGTGAAACCCCATCTCTACCAAAAATACAAAAAATTAGCGAGGTATGGTGGTGTGTACCTGTGGTTCCAGCTACTCAGGATGTTGAGGTGGGAGGACCGCTTGAGCCTGGGAAGTGCAAGTTGCAGTGAGCCGAGATTTTGCCACTACACTCCCATTTGGGTGACAGAGTGAGACCCTTTCTCAAAAACAAACTAATTAAAAAACCCTCCATTTTACAGATGAAGAAACTGAGTCATACAACTACTAAGAGAAACTGAGTCACTAATCACTCAGGTGGTCTGGCTCCAGCATCTGTACTCTTAATCTCTGCTCTATACTGCCCAAGACTTTTATAAAGTCAAGGGTTGAGTCACTGAAATGAGTTATTGGGATGGCTGTGTGGGAAGGGTGCTAAGTTCTTTCCTAAAGGTATGTGAGAATACAAAGGAAAGAAGCATCCTCCTTTTTACACACGTGAACTAGTGCATGCAAATCTGACACTCAGTGGGCCTGGGTGAAGGTGAGAATTTTATTGCTGAATGAGAGCCTCTGGGGACATCTTGCCAGTCAATGAGTCTCAGGTTCAATTTCCTTCTCAGTCTTGGAGTAACAGAAGCTCATGCATTTAATAAACGGAAATTTTGTATTGAAATGAGAGCCATTGGAAATCATTTACTCCAGACTCCTACTTATAAAAAGAGAAACTGAGGCTCAGAGAAGGGTGGGGACTTTCTCAGTATGACATGGAAATGATCAGGCTTGGATTCAAAGCTCCTGACTTTCTGTCTAGTGTATGTGCAGTGAGCCCCTTTTCCTCTAACTGAAAGAAGGAAAAAAAAATGGAACCCAAAATATTCTACATAGTTTCCATGTCACAGCCAGGGCTGGGCAGTCTCCTGTTATTTCTTTTAAAATAAATATATCATTTAAATGCATAAATAAGCAAACCCTGCTCGGGAATGGGAGGGAGAGTCTCTGGAGTCCACCCCTTCTCGGCCCTGGCTCTGCAGATAGTGCTATCAAAGCCCTGACAGAGCCCTGCCCATTGCTGGGCCTTGGAGTGAGTCAGCCTAGTAGAGAGGCAGGGCAAGCCATCTCATAGCTGCTGAGTGGGAGAGAGAAAAGGGCTCATTGTCTATAAACTCAGGTCATGGCTATTCTTATTCTCACACTAAGAAAAAGAATGAGATGTCTACATATACCCTGCGTCCCCTCTTGTGTACTGGGGTCCCCAAGAGCTCTCTAAAAGTGATGGCAAAGTCATTGCGCTAGATGCCATCCCATCTATTATAAACCTGCATTTGTCTCCACACACCAGTCATGGACAATAACCCTCCTCCCAGGTCCACGTGCTTGTCTTTGTATAATACTCAAGTAATTTCGGAAAATGTATTCTTTCAATCTTGTTCTGTTATTCCTGTTTCAATGGCTTAGTAGAAAAAGTACATACTTGTTTTCCCATAAATTGACAATAGACAATTTCACATCAATGTCTATATGGGTCGTTGTGTTTGCTGTGTTTGCAAAAACTCACAATAACTTTATATTGTTACTACTCTAAGAAAGTTACAACATGGTGAATACAAGAGAAAGCTATTACAAGTCCAGAAAATAAAAGTTATCATCTTGAGGCCTCAGCTTTCTAGGAATAATATCAATATTACAAAATTAATCTAACAATTATGAACAGCAATGAGATAATGTGTACAAAGTACCCAGACCTATGTGGTAGAGCATCAAGGAAGCGCATTGCGGAGCAGTTTTTTGTTTGTTTGTTTTTGTATTCTGTTTCGTGAGGCAAGGTTTCACTCTGCTGTCCAGGCTGGAGTGCAGTGGCAAGATCATGTCTCACTGCAGCCTTGACCTCCTG-A beta Thalassemia Pathogenic (Nov 25, 2019)869331
11-5301105-G-C not specified Uncertain significance (Mar 11, 2022)2278361
11-5301136-T-C not specified Uncertain significance (Apr 07, 2023)2535129
11-5301226-G-A not specified Uncertain significance (Sep 07, 2022)2362977
11-5301243-A-G not specified Uncertain significance (Jan 09, 2024)3205768
11-5301273-A-G not specified Uncertain significance (Jul 09, 2021)2235602
11-5301279-A-T not specified Uncertain significance (Sep 16, 2021)2250826
11-5301293-G-C not specified Uncertain significance (Sep 13, 2023)2592147
11-5301327-T-C not specified Uncertain significance (Jun 05, 2023)2552614
11-5301378-G-A not specified Uncertain significance (Jun 29, 2023)2599535
11-5301380-G-C not specified Uncertain significance (Nov 03, 2023)3205767
11-5301413-A-T not specified Uncertain significance (Jan 30, 2024)3205766
11-5301442-G-A not specified Uncertain significance (Dec 19, 2022)2301876
11-5301525-A-G not specified Uncertain significance (Aug 12, 2021)2243743

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
HBE1protein_codingprotein_codingENST00000380237 3237266
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.02000.758125691071256980.0000278
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.2087479.20.9340.00000391966
Missense in Polyphen2327.6050.83317379
Synonymous-0.4033734.01.090.00000198287
Loss of Function0.84735.050.5942.14e-763

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00002900.0000290
Ashkenazi Jewish0.000.00
East Asian0.0001090.000109
Finnish0.000.00
European (Non-Finnish)0.00001760.0000176
Middle Eastern0.0001090.000109
South Asian0.00003270.0000327
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: The epsilon chain is a beta-type chain of early mammalian embryonic hemoglobin.;

Recessive Scores

pRec
0.0873

Intolerance Scores

loftool
0.377
rvis_EVS
-0.01
rvis_percentile_EVS
53.19

Haploinsufficiency Scores

pHI
0.323
hipred
N
hipred_score
0.285
ghis
0.402

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
gene_indispensability_pred
N
gene_indispensability_score
0.120

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Hbb-y
Phenotype
normal phenotype;

Gene ontology

Biological process
blood coagulation;response to organic cyclic compound;oxygen transport;hydrogen peroxide catabolic process;protein heterooligomerization;cellular oxidant detoxification
Cellular component
cytosol;hemoglobin complex;haptoglobin-hemoglobin complex;blood microparticle
Molecular function
peroxidase activity;oxygen carrier activity;protein binding;oxygen binding;heme binding;haptoglobin binding;hemoglobin alpha binding;organic acid binding;metal ion binding